Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Operations: 2020-2024

Historic Cash from Operations for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to -$37.0 million.

  • Xeris Biopharma Holdings' Cash from Operations rose 321.94% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 133.53%. This contributed to the annual value of -$37.0 million for FY2024, which is 21.36% up from last year.
  • Xeris Biopharma Holdings' Cash from Operations amounted to -$37.0 million in FY2024, which was up 21.36% from -$47.0 million recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' Cash from Operations ranged from a high of -$37.0 million in FY2024 and a low of -$102.9 million during FY2022.
  • In the last 3 years, Xeris Biopharma Holdings' Cash from Operations had a median value of -$47.0 million in 2023 and averaged -$62.3 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first dropped by 18.59% in 2021, then spiked by 54.30% in 2023.
  • Xeris Biopharma Holdings' Cash from Operations (Yearly) stood at -$80.6 million in 2020, then dropped by 18.59% to -$95.5 million in 2021, then declined by 7.70% to -$102.9 million in 2022, then surged by 54.30% to -$47.0 million in 2023, then rose by 21.36% to -$37.0 million in 2024.